AGOURA HILLS, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), a leader in RNA-based therapeutics, announced today that its subsidiary Sapu Nano will formally introduce its Deciparticle™ nanomedicine platform and present its advancing clinical pipeline at BIO-Europe Spring 2026, where the company has been selected as a Presenting Company. The presentation will take place at: Event: BIO-Europe Spring 2026Session: Presenting Co ...